This proposal responds to NIH RFA-AI-05-002. It describes the University of Washington Clinical HIV Integrated Research Program (UW CHIRP). The purpose of the UW CHIRP is to perform exemplary, cost effective HIV prevention and therapeutic research in adults, adolescents, and children. The UW CHIRP has been formed by integration of four existing, NIH-funded, network-affiliated HIV clinical research sites (CRSs). These CRSs are the UW HIV Prevention Trials Unit (HPTU) CRS, UW AIDS Clinical Trials Unit (ACTU) CRS, UW Primary Infection Clinic (PIC) CRS, and the UW International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) CRS. An administrative unit called the UW Clinical Trials Unit (CTU) will oversee the CRSs. The four CRSs will collaborate with the HIV Prevention Trials Network (HPTN), AIDS Clinical Trials Group (ACTG), ACTG, and the IMPAACT Group, respectively. UW CHIRP has five specific aims: 1) Organize, integrate, and coordinate the infrastructure, personnel, and facilities of UW and our CRSs to maximize efficiency and cost-effectiveness in conducting Network clinical trials;2) Ensure that all elements of the UW CHIRP meet necessary regulatory requirements, and perform to the standards of each affiliated Network;3) Foster new investigators and clinical research staff, especially women and minorities, and provide our clinical trials expertise to our Mentoring Partners;4) Contribute scientific expertise to the HPTN, ACTG, and IMPAACT Networks to develop and implement relevant scientific agendas, and to design protocols to support these Networks'scientific agendas and research plans;and 5) Organize, integrate, and coordinate our outreach efforts and connections to the community, including continuing our Prevention and Treatment Community Advisory Boards (CABs), to maximize access and enrollment of a broad diversity of subjects into Network protocols, including women, racial/ethnic minorities, and youth. The proposal describes the organization and management plan for each part of UW CHIRP;the scientific expertise, scientific contributions, and mentoring experience of its highly experienced investigators;and the plans for community interactions that will focus on reaching women, minorities and youth. It describes three proposed international Mentoring Partnerships that are extensions of ongoing collaborations. The UW CHIRP brings together a highly productive, experienced team of domestic investigators, each of whom has made a significant contribution to HIV prevention and/or therapeutic research. With the new structure, UW CHIRP will increase collaborations and efficiencies, and will continue to make major contributions to HIV prevention and therapeutic research in order to impact the worldwide HIV/AIDS epidemic. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069434-06
Application #
8204500
Study Section
Special Emphasis Panel (ZAI1-MPM-A (M2))
Program Officer
Potter, Dara G
Project Start
2006-12-01
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
6
Fiscal Year
2012
Total Cost
$1,255,138
Indirect Cost
$446,682
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Drozd, Daniel R; Kitahata, Mari M; Althoff, Keri N et al. (2017) Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr 75:568-576
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Buchacz, Kate; Lau, Bryan; Jing, Yuezhou et al. (2016) Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis 214:862-72
De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80

Showing the most recent 10 out of 112 publications